Atomwise and Hansoh successfully identified potent hit compounds each having unique composition of matter for their first AI discovery program against drug-resistant oncology targets SHANGHAI & SAN FRANCISCO–(BUSINESS WIRE)– Hansoh Pharma (3692:HK), a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the expansion of their strategic partnership for […]
Atomwise News
San Francisco, CA – April 2, 2024 – Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter. The landmark study applied AtomNet to 318 targets through collaborations […]
SAN FRANCISCO–(BUSINESS WIRE)– Atomwise, a leader in using AI for small molecule drug discovery, today announced the nomination of its first AI-driven development candidate focused on TYK2 inhibition and the appointment of Neely Mozaffarian, MD, PhD as Chief Medical Officer. Dr. Mozaffarian brings over 25 years of immunology and clinical research experience to the role […]
Veteran drug hunter adds discovery expertise to technology-enabled biopharma company SAN FRANCISCO, Calif. — September 14, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer. Dr. Hirst brings more than 30 years of expertise in drug discovery […]